



NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate

February 14, 2019

Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms

WAYNE, Pa.--(BUSINESS WIRE)--Feb. 14, 2019-- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Humana, one of the nation's largest private health insurers, is now providing insurance coverage for the UroLift® System, a minimally invasive in-office treatment that provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH).^{1,2}

Humana insures more than 9.2 million lives through their commercial and Medicare Advantage products. With more than 3.5 million Medicare Advantage members, Humana is also one of the country's largest administrators of Medicare Advantage plans.

NeoTract also announced that an additional 90,000 lives are now covered for the UroLift System by Motion Picture Industry Pension & Health Plans (MPI), which is administered by Anthem Blue Cross – This is an encouraging step forward as Anthem Blue Cross is the only independent licensee of the Blue Cross Blue Shield Association not currently allowing member access to the UroLift System procedure. With these recent coverage decisions, a large majority of insured men in America now have access to the UroLift System procedure using their health insurance benefits.

"These coverage decisions are a major testament to the clinical benefits of the UroLift System for treating Benign Prostatic Hyperplasia (BPH), a common condition that significantly impacts the overall health of men with symptomatic BPH as well as the quality of life for those men and their partners," said Dave Amerson, president of Teleflex Interventional Urology business unit. "We are pleased to see the continued acceptance of the UroLift System as a standard-of-care therapy for patients with symptomatic BPH. This coverage milestone will expand lasting and durable symptom relief to millions of men, allowing them to return to a healthier and better quality of life."

BPH, also known as enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.³ BPH affects over 40 million men in the United States alone.⁴ If left untreated, the condition can worsen over time and cause permanent bladder damage.⁵

The UroLift System is the only minimally invasive treatment option that has been shown to provide rapid and durable symptomatic and urinary flow rate improvement without causing sexual dysfunction.^{*1,6-9} The Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.

*No instances of new, sustained erectile or ejaculatory dysfunction.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.^{*1,9} Patients also experienced a significant improvement in quality of life. Over 80,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

*No instances of new, sustained erectile or ejaculatory dysfunction

¹Roehrborn, J Urology 2013 LIFT Study

² Shore, Can J Urol 2014 Local Study

³ Speakman et al. 2014 BJUI International

⁴ NeoTract US Market Model estimates for 2018 based on IQVIA Health Drug and Procedure data

⁵ Tubaro et al. 2003 Drugs Aging

⁶ AUA BPH Guidelines 2003, 2010, 2018

⁷ Naspro, Eur Urol 2009

⁸ Montorsi, J Urol 2008

⁹ McVary, J Sex Med 2016

MAC00969-01 Rev A

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190214005045/en/>

Source: Teleflex Incorporated

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com